Biotest AG
XETRA:BIO

Watchlist Manager
Biotest AG Logo
Biotest AG
XETRA:BIO
Watchlist
Price: 40.2 EUR -4.74%
Market Cap: 1.5B EUR

Biotest AG
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Biotest AG
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Biotest AG
XETRA:BIO
Revenue
€635.2m
CAGR 3-Years
7%
CAGR 5-Years
8%
CAGR 10-Years
1%
BioNTech SE
NASDAQ:BNTX
Revenue
€2.8B
CAGR 3-Years
-47%
CAGR 5-Years
91%
CAGR 10-Years
N/A
CureVac NV
NASDAQ:CVAC
Revenue
€535.2m
CAGR 3-Years
73%
CAGR 5-Years
98%
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Revenue
€84.8m
CAGR 3-Years
-17%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Heidelberg Pharma AG
XETRA:HPHA
Revenue
€6.8m
CAGR 3-Years
58%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Formycon AG
XETRA:FYB
Revenue
€69.7m
CAGR 3-Years
24%
CAGR 5-Years
15%
CAGR 10-Years
19%
No Stocks Found

Biotest AG
Glance View

Market Cap
1.6B EUR
Industry
Biotechnology

Biotest AG, headquartered in Dreieich, Germany, is a pivotal player in the field of biopharmaceuticals, with a particular focus on blood plasma-derived products. The company traces its origins back to 1946 when it was founded as a laboratory for blood testing, and since then, it has transformed into a significant force in the healthcare sector. Biotest operates on a vertically integrated business model, from collecting plasma to the manufacturing and distribution of therapeutic proteins. The company primarily produces and markets products like immunoglobulins, coagulation factors, and albumins, which are essential for treating immune system deficiencies, blood clotting disorders, and various other ailments. These products serve not only to improve the quality of life for patients but are critical lifelines for those with chronic and acute conditions. Revenue generation at Biotest revolves around a three-pronged strategy: plasma collection, manufacturing, and commercialization of its proprietary therapies. The process begins with the acquisition of raw plasma through an extensive network of collection centers. This plasma is then processed and transformed into high-value therapeutic products in sophisticated manufacturing facilities. Biotest’s revenue stream is bolstered by its strong presence in international markets, serving hospitals, clinics, and healthcare systems with high demand for its specialized products. By leveraging its in-depth expertise in plasma technology and robust infrastructure, Biotest AG has carved a niche, ensuring a steady flow of returns while contributing significantly to advancements in treating rare diseases and fostering global health betterment.

BIO Intrinsic Value
HIDDEN
Show

See Also

What is Biotest AG's Revenue?
Revenue
635.2m EUR

Based on the financial report for Mar 31, 2025, Biotest AG's Revenue amounts to 635.2m EUR.

What is Biotest AG's Revenue growth rate?
Revenue CAGR 10Y
1%

Over the last year, the Revenue growth was -16%. The average annual Revenue growth rates for Biotest AG have been 7% over the past three years , 8% over the past five years , and 1% over the past ten years .

Back to Top